Ядерная медицина и лучевая терапия

What do Dosimetric Errors Encountered in Prostate Implant Brachytherapy tell us about α/β?

Abstract

Paul Mobit, Ephraim Agyingi, Satyaseelan Packianathan and Claus Chunli Yang

Objective: To determine the α/β ratio of prostate cancer using the linear quadratic model taking into account different radiation prescription doses and RBE for low energy gamma rays.

Methods and material: The linear quadratic model was used to evaluate the α/β ratio for prostate cancer taking into account the dosimetric errors resulting from seed displacements in prostate permanent implant brachytherapy with 125I and 103Pd. The study assessed the variability of the α/β ratio with different prescribed external beam radiation therapy doses and published values of the relative biological effectiveness (RBE) for both 125I and 103Pd. The biological effective dose (BED) for prostate implant brachytherapy was equated to the external beam radiation therapy dose to derive an equation for α/β ratio.

Results: The results showed that the α/β ratio for prostate cancer varied between 1 and 4.5 for an RBE of 1.0 when an external beam dose of 78.0 Gy was prescribed. When published values of RBEs were incorporated into the analysis, the α/β ratio varied between 0.37 and 4.4. The α/β ratio changed by 30% when the external beam radiation dose was increased from 72 Gy to 80 Gy.

Conclusions: Assuming an average reduction in implanted seeds brachytherapy dose between 10–20% using 125I or 103Pd, the realistic value of the α/β ratio for prostate tumors likely lies between 0.7 and 2.0.